EGFR targeted therapy in lung cancer; an evolving story. (2017)

• Record Type: Journal Article
• Authors: Bartholomew, C.; Eastlake, L.; Dunn, P.; Yiannakis, D.
• Is Part Of: Respiratory medicine case reports. Volume 20(2017)
• Page Start: 137
• Page End: 140
• Publication Date: 2017
• Subjects: Non-small cell lung cancer -- EGFR -- Tyrosine kinase inhibitors (TKI) -- Erlotinib (Tarceva) -- Osimertinib (Tagrisso) -- Acquired T790M mutation; Respiratory organs -- Diseases -- Periodicals; Chest -- Diseases -- Periodicals; Respiratory Tract Diseases -- Periodicals; Respiratory System -- Periodicals; Chest -- Diseases; Respiratory organs -- Diseases; Electronic journals; Periodicals; 616.2
• DOI: 10.1016/j.rmcr.2017.01.016
• Languages: English
• ISSNs: 2213-0071

Abstract

Abstract: Specific oncogenes with driver mutations, such as the Epidermal Growth Factor Receptor (EGFR 1) gene can lead to non-small-cell lung cancer formation. Identification of these oncogenes, their driver mutations and downstream effects allow the targeting of these pathways by drugs. Such personalised therapy has become an important strategy in combating lung cancer and highlights the need to test for these mutations. Tyrosine Kinase Inhibitors (TKIs) against EGFR, such as Erlotinib, are able to halt these tumour promoting properties in non-small-cell lung cancers. Third generation EGFR TKIs, such as Osimertinib, are focussing on resulting acquired TKI resistance. Here we report the clinical course of a patient with metastatic non-small-cell lung cancer who has undergone EGFR targeted therapy and been further challenged by TKI acquired resistance. Her extended survival and maintained quality of life are a consequence of these modern, genotype-targeted, personalised metastatic non-small-cell lung cancer therapies.